Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label phase 3 LITESPARK-012 study
Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label phase 3 LITESPARK-012 study. // Annals of Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S0923753426080713?dgcid=rss_sd_all
Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label phase 3 LITESPARK-012 study. Annals of Oncology. https://www.sciencedirect.com/science/article/pii/S0923753426080713?dgcid=rss_sd_all
“Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label phase 3 LITESPARK-012 study.” Annals of Oncology.
@article{article36230,
title = {Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label phase 3 LITESPARK-012 study},
journal = {Annals of Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S0923753426080713?dgcid=rss_sd_all}
}